Related Experiment Video
Updated: Jun 23, 2026
Intramyocardial Cell Delivery: Observations in Murine Hearts
Published on: January 24, 2014
Repeated autologous bone marrow mononuclear cell therapy in patients with large myocardial infarction
Kang Yao1, Rongchong Huang, Aijun Sun
1Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Insights
Repeat administration of bone marrow mononuclear cells (BMC) significantly improved left ventricular ejection fraction and reduced infarct size in patients with acute myocardial infarction (AMI). This suggests BMC therapy is a safe and feasible treatment option for AMI.
Area of Science:
- Cardiovascular Medicine
- Regenerative Medicine
- Cell Therapy
Background:
- Large acute myocardial infarction (AMI) often leads to significantly reduced left ventricular ejection fraction (LVEF).
- Current treatments aim to restore cardiac function, but further therapeutic strategies are needed.
Purpose of the Study:
- To evaluate the efficacy of repeat administration of bone marrow mononuclear cells (BMC) compared to a single infusion in patients with large AMI.
- To assess the safety and feasibility of BMC therapy in this patient population.
Main Methods:
- Thirty-nine patients with ST-elevation AMI and LVEF 20-39% were randomized post-percutaneous coronary intervention.
- Groups received either a single BMC infusion, repeated BMC infusions (at 3-7 days and 3 months), or placebo.
- Left ventricular function and infarct size were assessed using magnetic resonance imaging (MRI) over 12 months.
Main Results:
- Repeated BMC administration resulted in a significantly greater increase in LVEF (11.7%) compared to single BMC infusion (7.2%) or placebo (2.9%) after 12 months.
- Myocardial infarct size decreased significantly more in the repeated BMC group compared to the single BMC infusion group.
- No severe complications were observed with BMC administration.
Conclusions:
- Repeated administration of BMC appears to be a safe and feasible therapeutic strategy for patients with large AMI.
- This approach shows promise for improving cardiac function and reducing infarct size post-myocardial infarction.
Aims:
We sought to determine whether repeat administration of bone marrow mononuclear cells (BMC) can improve left ventricular function compared with a single infusion in patients with large acute myocardial infarction (AMI).
Methods And Results:
Thirty-nine patients with a ST-elevation AMI of the anterior wall and a significantly decreased left ventricular ejection fraction (LVEF 20-39%) were randomly assigned to three groups following primary percutaneous coronary intervention: Group A (n = 12) received a single intracoronary infusion of BMC (1.9 +/- 1.2 x 10(8)) at 3-7 days after AMI; Group B (n = 15) received BMC administration both at 3-7 days (2.0 +/- 1.4 x 10(8)) and at 3 months (2.1 +/- 1.7 x 10(8)); and the control group (CON, n = 12) received one placebo injection at 3-7 days. We noted no severe complications associated with the BMC transfer. The increase in LVEF evaluated by magnetic resonance imaging (MRI) after 12 months in Group B (11.7 +/- 2.6%) was significantly greater than that in Group A (7.2 +/- 1.6%, P < 0.001) or in CON (2.9 +/- 2.0%, P < 0.001). Magnetic resonance imaging-derived myocardial infarct size decreased significantly in Group B compared with Group A (11.3 +/- 2.7% vs. 6.3 +/- 1.6%, P < 0.001).
Conclusion:
Data from this preliminary study suggest that repeated BMC administration might be a safe and feasible therapeutic strategy for patients with large AMI.
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:14Myocarditis III: Medical Management